Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GLAUKOS CORPORATION

(GKOS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Glaukos : Agrees to Stop Patent Litigation Against Ivantis in Exchange for $60 Million Payment, Royalty Share

09/15/2021 | 07:50am EST


ę MT Newswires 2021
All news about GLAUKOS CORPORATION
11/22GLAUKOS : Investor Presentation November 2021
PU
11/22GLAUKOS CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
11/19Glaukos Announces Participation in Upcoming Investor Conferences
BU
11/11Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Aca..
BU
11/09Berenberg Bank Adjusts Glaukos' Price Target to $60 From $65, Maintains Buy Rating
MT
11/08GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
11/05Jefferies Adjusts Price Target on Glaukos to $60 from $54, Keeps Hold Rating
MT
11/04GLAUKOS : Q3 Earnings Snapshot
AQ
11/04Glaukos Corporation Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/04Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Loss $-0.21, vs. Street Est of $-0.2..
MT
More news
Analyst Recommendations on GLAUKOS CORPORATION
More recommendations
Financials (USD)
Sales 2021 288 M - -
Net income 2021 -43,1 M - -
Net cash 2021 177 M - -
P/E ratio 2021 -41,9x
Yield 2021 -
Capitalization 2 016 M 2 016 M -
EV / Sales 2021 6,38x
EV / Sales 2022 6,88x
Nbr of Employees 653
Free-Float 96,1%
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | GKOS | US3773221029 | MarketScreener
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 41,73 $
Average target price 54,38 $
Spread / Average Target 30,3%
EPS Revisions
Managers and Directors
Thomas William Burns President, Chief Executive Officer & Director
Joseph E. Gilliam CFO, CAO & Senior VP-Corporate Development
William J. Link Chairman
L. Jay Katz Chief Medical Officer
Tomas Navratil Senior Vice President-Research & Development
Sector and Competitors